Clinical Challenges

Unanticipated Toxicity to Capecitabine

Susan Moore

cardiotoxicity, capecitabine
ONF 2009, 36(2), 149-152. DOI: 10.1188/09.ONF.149-152

Jump to a section

    References

    Etienne, M. C., Lagrange, J. L., Dassonville, O., Fleming, R., Thyss, A., Renee, N., et al. (1994). Population study of dihydro-pyrimidine dehydrogenase in cancer patients. Journal of Clinical Oncology, 12(11), 2248-2253.
    Ezzeldin, H., & Diasio, R. (2004). Dihydro-pyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouricil administration. Clinical Colorectal Cancer, 4(3), 181-189.
    Fischel, J. L., Etienne, M. C., Spector, T., Formento, P., Renee, N., & Milano, G. (1995). Dihydropyrimidine dehydrogenase: A tumoral target for fluorouracil modulation. Clinical Cancer Research, 1(9), 991-996.
    Franco, D. A., & Greenberg, H. S. (2001). 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency. Neurology, 56(1), 110-112.
    Johnson, M. R., & Diasio, R. B. (2001). Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Advances in Enzyme Regulation, 41(1), 151-157.
    Lu, Z., Zhang, R., & Diasio, R. B. (1993). Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Research, 53(22), 5433-5438.
    Mattison, L. K., Ezzeldin, H., Carpenter, M., Modak, A., Johnson, M. R., & Diasio, R. B. (2004). Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clinical Cancer Research, 10(8), 2652-2658.
    Mattison, L. K., Fourie, J., Desmond, R. A., Modak, A., Saif, M. W., & Diasio, R. B. (2006). Increased prevalence of dihydro-pyrimidine dehydrogenase deficiency in African Americans compared with Caucasians. Clinical Cancer Research, 12(18), 5491-5495.
    Mattison, L. K., Fourie, J., Hirao, Y., Koga, T., Desmond, R. A., King, J. R., et al. (2004). The uracil breast test in the assessment of dihydropyrimidine dehydrogenase activity: Pharmacokinetic relations between expired 13CO2 and plasma [2-13C] dihydrouracil. Clinical Cancer Research, 12(2), 549-555.
    Mattison, L. K., Soong, R., & Diasio, R. B. (2002). Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics, 3(4), 485-492.
    McCollum, A. D., Catalano, P., & Haller, D. (2002). Outcomes and toxicity in African American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. Journal of the National Cancer Institute, 94(15), 1160-1167.
    Milano, G., Etienne, M. C., Pierrefite, V., Barberi-Heyob, M., Deporte-Fety, R., & Renee, N. (1999). Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. British Journal of Cancer, 79(3/4), 627-630.
    Morel, A., Boisdron-Celle, M., Fey, L., Soulie, S., Craipeau, M. C., Traore, S., et al. (2006). Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Molecular Cancer Therapeutics, 5(11), 2895-2904.
    National Comprehensive Cancer Network. (2008). NCCN Clinical Guidelines in Oncology™: Prevention and treatment of cancer-related infections. Retrieved November 17, 2008, from http://nccn.org/professionals/physician_gls/PDF/infections.pdf
    Omura, K. (2003). Clinical implications of dihydropyrimidine (DPD) activity in 5FU-based chemotherapy: Mutations in the DPD gene and DPD inhibitory fluoropyrimidines. International Journal of Clinical Oncology, 8(3), 132-138.
    Oncology Nursing Society. (2005). Prevention of infection PEP® resource card. Retrieved November 17, 2008, from http://ons.org/outcomes/volume1/prevention/pdf/InfectionPEPCard.pdf
    Oncology Nursing Society. (2008). Diarrhea ONS PEP® resource card. Retrieved November 12, 2008, from http://www.ons.org/outcomes/volume4/diarrhea/pdf/ShortCard_Diarrhea.pdf
    Roche Laboratories. (2006). Xeloda [prescribing information]. Retrieved November 3, 2008, from http://www.rocheusa.com/products/xeloda/pi.pdf
    Saif, M. W., Ezzeldin, H., Vance, K., Sellers, S., & Diasio, R. B. (2007). DPYD*2A mutation: The most common mutation associated with DPD deficiency. Cancer Chemotherapy Pharmacology, 60(4), 503-507.
    Saif, M. W., Syrigos, K., Mehra, R., Mattison, L. K., & Diasio, R. B. (2007). Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: Experience of four years. Pakistan Journal of Medical of Sciences Quarterly, 23(6), 832-839.
    Schwab, M., Zanger, U. M., Marx, C., Schaeffeler, E., Klein, K., Dippon, J., et al. (2008). Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group. Journal of Clinical Oncology, 26(13), 2131-2138.
    van Kuilenburg, A. B., Meinsma, R., Zoetekouw, L. & Van Gennip, A. H. (2002). Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g > a mutation. International Journal of Cancer, 101(3), 253-258.
    van Kuilenburg, A. B., van Lenthe, H., Tromp, A., Veltman, P., & Van Gennip, A. H. (2000). Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clinical Chemistry, 46(1), 9-17.
    van Kuilenburg, A. B., Vreken, P., Abeling, N., Bakker, H. D., Meinsma, R., Van Lenthe, H., et al. (1999). Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Human Genetics, 104(1), 1-9.
    van Kuilenburg, A. B., Vreken, P., Beex, L., Meinsma, R., van Lenthe, H., De Abreu, R. A., et al. (1997). Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. European Journal of Cancer, 33(13), 2258-2264.
    Etienne, M. C., Lagrange, J. L., Dassonville, O., Fleming, R., Thyss, A., Renee, N., et al. (1994). Population study of dihydropyrimidine dehydrogenase in cancer patients. Journal of Clinical Oncology, 12(11), 2248-2253.
    Fischel, J. L., Etienne, M. C., Spector, T., Formento, P., Renee, N., & Milano, G. (1995). Dihydropyrimidine dehy-drogenase: A tumoral target for fluorouracil modulation. Clinical Cancer Research, 1(9), 991-996.
    Johnson, M. R., & Diasio, R. B. (2001). Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Advances in Enzyme Regulation, 41(1), 151-157.
    Mattison, L. K., Soong, R., & Diasio, R. B. (2002). Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics, 3(4), 485-492.
    Milano, G., Etienne, M. C., Pierrefite, V., Barberi-Heyob, M., Deporte-Fety, R., & Renee, N. (1999). Dihydropyrimidine dehydrogenase deficiency. British Journal of Cancer, 79(3/4), 627-630.
    Omura, K. (2003). Clinical implications of dihydropyrimidine (DPD) activity in 5FU-based chemotherapy: Mutations in the DPD gene and DPD inhibitory fluoropyrimidines. International Journal of Clinical Oncology, 8(3), 132-138.
    van Kuilenburg, A. B. (2006). Screening for dihydropyrimidine dehydrogenase deficiency: To do or not to do, that's the question. Cancer Investigation, 24(2), 215-217.
    van Kuilenburg, A. B., van Lenthe, H., Tromp, A., Veltman, P., & Van Gennip, A. H. (2000). Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clinical Chemistry, 46(1), 9-17.
    van Kuilenburg, A. B., Vreken, P., Beex, L., Meinsma, R., van Lenthe, H., De Abreu, R. A., et al. (1997). Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. European Journal of Cancer, 33(13), 2258-2264.